Amedisys (AMED) Tops Q2 EPS by 53c, Revs Beat

Amedisys (NASDAQ: AMED) reported Q2 EPS of $1.34, $0.53 better than the analyst estimate of $0.81. Revenue for the quarter came in at $485 million versus the consensus estimate of $469.13 million.

Paul B. Kusserow, President and Chief Executive Officer stated, “I am very proud of our second quarter results which have allowed us to reissue our full year 2020 guidance ranges, but once again, more proud of our employees that delivered these results during such a momentous and unprecedented time in our nation’s history. Our front-line heroes continue to provide the highest quality care to our patients, wherever they call home even in the face of this Public Health Emergency. They have adapted to our COVID-19 policies and procedures, utilized PPE to protect both themselves and our patients, quickly implemented telehealth for additional patient touch points and have gone above and beyond to be great partners to our referral sources. The pandemic continues to highlight the importance of caring for people in their homes, wherever they call home, and as such has positioned Amedisys for continued growth in the future. A special thank you to all our essential healthcare workers - you are true heroes and none of this would be possible without you.”

GUIDANCE:

Amedisys sees FY2020 EPS of $4.84-$5.06, versus the consensus of $4.54. Amedisys sees FY2020 revenue of $2.04-2.07 billion, versus the consensus of $2.04 billion.

For earnings history and earnings-related data on Amedisys (AMED) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c